ClinicalTrials.gg
CompletedNCT02466373Clokin1Updated Jul 30, 2018

Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients

A Phase 3 interventional study of Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml in Delirium and Critical Illness, sponsored by Deventer Ziekenhuis. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-30.

Sponsored by Deventer Ziekenhuis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Delirium with a site in Netherlands — 3 open to participants now, 3 under way, 1 of them phase 3. Delirium · Netherlands.

Enrollment
18th of 18
32 · median 174
Started
2016
with 2 others
Phase 3
5 of 31
1 open now
Registered
16th of 31
by date
Lead sponsor
2 of 31
Deventer Ziekenhuis

Among the 31 studies in Delirium with a site in Netherlands, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 16th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

3 of the 31 studies in Delirium with a site in Netherlands are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Delirium with a site in Netherlands, or all of them as a file.
02

Study summary

This study is developed for assessing the pharmacodynamic and pharmacokinetic properties of intravenous (IV) clonidine in critically ill patients on the ICU, and to estimate the optimal dosing strategy for IV clonidine.

Read the detailed description

Many patients in intensive care units (ICU's) require sedation and analgesia to tolerate mechanical ventilation and other ICU procedures. Commonly used GABA-ergic anaesthetics like propofol, midazolam and morphine have potential adverse effects that may increase morbidity, prolong ICU stay and provoke delirium. Recent studies have shown that sedation with alpha-2-adrenergic agonists may lead to a reduction of the total amount of gamma-aminobutyric acid (GABA) -ergic anaesthetics and reduction of delirium1In clinical practice the alpha-2-adrenergic agent clonidine is widely used off label as an add-on sedative in mechanically ventilated patients who suffer from delirium, but there are no large studies proving that this therapy is effective and safe. Limited information exists on the pharmacokinetics of iv clonidine, especially in ICU patients. Besides, dosing regimens of clonidine differ widely among ICU's in the Netherlands, and in the literature.

The sample size required for pharmacokinetic modelling with an acceptable level of precision is inversely related to the number of blood samplings taken from each individual. Population pharmacokinetic experiments that have been published have generally used 50 or more subjects. However, in the investigators study a relatively large number of blood samples are taken (>10 per subject when the protocol is completed, see section 6.3). THe investigators estimate that sufficient precision can be obtained with a sample size of 24 subjects, generating an estimated 240 to 360 blood samples.

In a recent publication of a computer simulated population pharmacokinetics of an absorption model using a design that involved 6 samplings per subject, it was estimated that a two-compartment first-order model would need 50 subjects (i.e. 300 blood samplings) to obtain a model with 50% precision and a power of 0.8.

The investigators 24 subjects will be treated with 3 different doses of clonidine (600, 1200 and 1800 µg/day), that is 8 per treatment arm.

On top of this, 8 patients receiving no clonidine will serve as a reference group, in order to interpret hemodynamic and safety data, and to illustrate dose-response relationships.

03

Conditions studied

  • Delirium
  • Critical Illness

Keywords

  • clonidine
  • pharmacodynamics
  • pharmacokinetics
  • intensive care
  • delirium
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, a subject must be:

  • at least 18 years of age
  • intubated
  • sedated at the start of the study. Because of the high incidence of delirium on the ICU in all age categories, all age groups > 18 years will be included

Exclusion criteria

Exclusion Criteria:

  • Severe neurotrauma,
  • Severe dementia (living in a nursing home)
  • Inability to speak Dutch or English, which is one of the causes of not being able to use the CAM-ICU.
  • The use of clonidine during the 96 hours before the start of the study.
  • Bradycardia (\<50/min)
  • Severe hypotension (MAP \< 65 after volume resuscitation and vasopressors)
  • Pregnancy and lactation (pregnancy test are routinely performed in premenopausal women on the ICU).
  • Epilepsy
  • Known clonidine intolerance
  • Liver cirrhosis ( class C)
  • Recent and acute myocardial infarction
  • Severe heart failure ( \< 30%)
  • Second or third degree atrioventricular (AV)-block without a permanent pacemaker
  • Expected transfer to another hospital.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • No intervention
    No clonidine

    No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms

  • Experimental
    Clonidine 600mcg

    4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.

    Drug: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml

  • Experimental
    Clonidine 1200mcg

    * 4 patients receive 1200 µg/day of clonidine without loading schedule. * 4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h.

    Drug: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml

  • Experimental
    Clonidine 1800mcg

    * 4 patients receive 1800 µg/day of clonidine without loading schedule. * 4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h.

    Drug: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml

Interventions

  • DrugClonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml

    Drug page: ClonidineStudies of ClonidineClonidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    clonidine intravenous

    Also known as: Boehringer Ingelheim, RVG 06055

06

What researchers measure

Primary outcomes

  1. clonidine plasma concentrations

    pharmacokinetic and pharmacodynamic properties of intravenous clonidine in ICU patients Clonidine plasma concentration at start of infusion at t=2, t=4, t=8 and t=12 h Clonidine plasma concentration during study, once daily Clonidine plasma concentration after stopping infusion at t=ω+8, t=ω+16, t=ω+24 h, and t=ω+48 h (ω= end of infusion).

    Time frame: up to 7 days

Secondary outcomes

  1. heart rate

    Heart rate 2-hrly for the first 12 h, 8-hrly thereafter

    Time frame: up to 7 days

  2. blood pressure

    Blood pressure 2-hrly for the first 12 h, 8-hrly thereafter

    Time frame: up to 7 days

  3. delirium

    delirium rating scale, CAM-ICU 3 times daily

    Time frame: up to 7 days

  4. use of antipsychotics

    additional use of haloperidol or sedatives, measured in total amount during the investigational period

    Time frame: up to 7 days

07

Study locations

1 site
  • Deventer Hospital
    Deventer, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Apr 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2015
First posted
Jun 9, 2015
Start
Dec 2016
Primary completionActual
Apr 5, 2018
CompletionActual
Apr 5, 2018
Last update
Jul 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02466373
Lead sponsor
Deventer Ziekenhuis
Responsible party
M. Zeeman (drs M. Zeeman, Deventer Ziekenhuis) — Principal investigator
First posted
Jun 9, 2015
Start date
Dec 2016
Primary completion
Apr 5, 2018
Completion
Apr 5, 2018
Last update
Jul 30, 2018

Study contacts

Huub Oever v/d
principal investigator · Deventer Ziekenhuis

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clonidine

Start the discussion